Pure Global AI
NCT05993247Not yet recruiting

Efficacy of Probiotics for NSAID-induced Enteropathy in Arthritis Patients

Efficacy of Probiotics for Non-steroidal Anti-inflammatory Drug-induced Enteropathy in Arthritis Patients: A Double-blinded Pilot Randomized Controlled Trial
Jae Myung ParkPhase 2ClinicalTrials.govcombination product
Verified
Study focus
Disease/Condition
Osteoarthritis
Drug/Device/Intervention
Probiotics capsule
Study type
Interventional
Intervention type
combination product
Sponsor & location
Primary sponsor
Jae Myung Park
Funder
Seoul St. Mary's Hospital
Timeline & enrollment
Phase
Phase 2
Start date
Aug 20, 2023
End date
Aug 31, 2025
Enrollment
36 participants
Primary outcome

Changes in the small bowel injuries on capsule endoscopy

Summary

This study aimed to investigate the efficacy of probiotics as a preventive agent for
 NSAID-induced enteropathy. Arthritis patients are randomly divided into probiotic and placebo
 groups, and the drug is administered for eight weeks. Before and after drug administration,
 the patient's symptoms/degree of small bowel injuries on capsule endoscopy/microbiome
 composition and diversity were investigated.

ICD-10 classifications
Other hypertrophic osteoarthropathyOther specified osteochondropathiesPolyarthritis, unspecifiedOther osteochondropathiesOsteochondritis dissecans
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05993247
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05993247 through Pure Global AI's free database. This Phase 2 trial is sponsored by Jae Myung Park and is currently Not yet recruiting. The study focuses on Osteoarthritis. Target enrollment is 36 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.